Clinical Trials and Studies
Some clinical trials have suspended enrollment until further notice due to COVID-19 considerations.
Blood Disorders and Hematologic Cancers
- Acute Myeloid Leukemia: Venetoclax and Azacitidine Study
- Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Chronic Graft-Versus-Host Disease Treatment Study
- Chronic Lymphocytic Leukemia in Patients 70 Years of Age and Older Treatment Study
- Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Treatment Study
- Conditioning Therapy for Patients with MDS/AML Undergoing Hematopoietic Cell Transplantation
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria
- Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study
- Drug Treatment Study for Children with Hemophilia A
- Drug Treatment Study for High Grade B-Cell Lymphomas
- Drug Treatment Study for Patients with Follicular Lymphoma
- Evaluation of Pediatric Palliative Inpatient Process
- FLT3 Mutated Acute Myeloid Leukemia Treatment Study
- Follicular Lymphoma Treatment Study
- Health Literacy and Numeracy in Adolescent Patients with Hemophilia A and B Study
- Hemophilia A or B Treatment Study
- Hemophilia A Treatment Study
- Hodgkin Lymphoma and CD30-Expressing Peripheral T-cell Lymphoma Treatment Study
- Luspatercept versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis
- Maintenance Study For Patients With Residual Myeloma Post-Transplant
- Mantle Cell Lymphoma Treatment Study
- Mapping of CD34+ Cells From Healthy Participants and Patients with Myelofibrosis and Polycythemia Vera
- Molecular and Clinical Biology of von Willebrand Disease Study
- MYC-Associated B-Cell Lymphomas Treatment Study
- Myelofibrosis Treatment Study
- Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Ruxolitinib
- National Registry of All Persons with Bleeding and Clotting Disorders
- Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
- Nivolumab and Combination Chemotherapy in Treating Participants with Diffuse Large B-Cell Lymphoma
- PIONEER Study: Avapritinib in Patients with Indolent Systemic Mastocytosis
- Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
- Relapsed or Refractory Follicular Lymphoma Treatment Study
- Relapsed or Refractory Mantle Cell Lymphoma Treatment Study
- Relapsed/Refractory Hodgkin Lymphoma Treatment Study
- Specimen Collection from ALL or CML Patients for the Xpert BCR-ABL Ultra p190 Test
- Specimen Collection from ALL or CML Patients with a Detectable BCR-ABL p190 Fusion Transcript Level
- Study for Patients with Acute Lymphoblastic Leukemia
- Study for Patients with Acute Myelogenous Leukemia
- Study for Patients with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
- Study of Biomarkers in Hemophilic Arthropathy
- Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders
- Study of Uproleselan Administered with Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Study Treating Patients With High-Risk Smoldering Myeloma
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- The National Myelodysplastic Syndromes Study
- Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Study
- Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Study
- Treatment for Adults with Warm Autoimmune Hemolytic Anemia
- Treatment Study for Children with Hemophilia B
- Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
- Treatment Study for Older Patients with Acute Lymphoblastic Leukemia
- Treatment Study for Patients with Diffuse Large B-Cell Lymphoma After aHCT
- Treatment Study for Patients with FLT3/ITD Acute Myeloid Leukemia in First Complete Remission
- Treatment Study for Patients with HER2-Expressing Cancers
- Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
- Treatment Study for Patients with Marginal Zone Lymphoma
- Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
- Treatment Study for Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Treatment Study for Patients with Rare Tumors
- Treatment Study for Patients with Relapsed/Refractory T-Cell Lymphoma
- Treatment Study for Patients with Untreated Mantle Cell Lymphoma
- Treatment Study for Pediatric Patients with Hemophilia A
- Treatment Study for Subjects with Myelofibrosis Who Have Failed a JAK Inhibitor
- Treatment Study for Subjects with Severe Hemophilia A or B
- Treatment Study for the Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma
- Treatment Study for Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Venetoclax with Azacitidine for Newly Diagnosed Myelodysplastic Syndrome
Brain Tumors
- Genetic Testing in Guiding Treatment for Patients with Brain Metastases
- Meningioma Drug Treatment Study
- Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma that has been Completely Removed by Surgery
- Radiation Therapy Study for Patients with IDH Mutant Grade II or III Glioma
- Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
- The MATCH Screening Trial
Breast Cancer
- A Study of Serum Folate Levels in Patients Treated with Olaparib
- Advanced or Metastatic HER2+ Breast Cancer Treatment Study
- Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection
- Breast Cancer Collaborative Registry
- Breast Cancer Microbiome Study
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-Surgery Chemo and Targeted Therapy
- Drug Treatment Study for First-Line HER2-Positive Metastatic Breast Cancer
- Estrogen Receptor Status Study
- Hypofractionated Radiation Therapy After Mastectomy in Patients With Stage IIa-IIIa Breast Cancer
- Limited Metastatic Breast Cancer Treatment Study
- Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer Treatment Study
- Radiation Therapy Treatment Study for Patients with Early-Stage Breast Cancer
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
- Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- Study Assessing the Accuracy of Tumor Biopsies After Chemotherapy
- Study of Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer
- Study of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
- The CompassHER2 RD Trial for High Risk HER2-Positive Breast Cancer
- The MATCH Screening Trial
- Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer
- Treating Patients With Triple-Negative Breast Cancer
- Treatment Study for Patients with Node-Positive Breast Cancer
- Treatment Study for Patients with Selected Incurable Cancers
- Treatment Study for Triple-Negative Breast Cancer or Renal Cell Carcinoma
Gastrointestinal Cancers
- Adenoma and Second Primary Prevention Trial
- Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Treatment Study
- Advanced/Metastatic Colorectal Cancer with HER-2 Amplification Treatment Study
- BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Colonoscopy Research Study
- Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study
- Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
- Experimental Drug Treatment Study for Patients with Specific Solid Tumors
- Growth of Colon Tissue to Evaluate GI
- High Risk Anal Cancer Treatment Study
- Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source
- Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas Treatment Study
- Oral Health Study
- PANOVA-3 Study for Patients with Locally-Advanced Pancreatic Adenocarcinoma
- Polyp Removal Research Study
- Refractory Small Bowel Adenocarcinoma Treatment Study
- Retrospective Chart Review of Patients with Fibrolamellar Carcinoma
- Study for Patients with Colorectal Cancer or Colorectal Lesion
- Study for Patients with Hepatocellular Carcinoma (HCC)
- Study for Patients with Pancreatic Cancer
- Study of Eating Patterns and Alcohol Consumption in Patients with Advanced Tubular Adenoma
- Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
- The COMMIT Study: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
- The DECREASE Study: Treatment of Early-Stage Anal Cancer
- The MATCH Screening Trial
- Treatment Study for Patients with HER2-Expressing Cancers
- Treatment Study for Patients with High Risk Stage II-IIIB Anal Cancer
- Treatment Study for Patients with Selected Incurable Cancers
- Treatment Study for Patients With Stage III Colon Cancer
- Treatment Study for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
- Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Genitourinary Cancers
- ADAPT Study for Bladder Cancers Not Invading Muscle Tissue
- BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Treatment Study
- Chemoradiotherapy Study for Patients with Localized Muscle Invasive Bladder Cancer
- Drug Treatment Study with Radiation in Advanced Tumors
- Endometrial Cancer Medication Treatment Study
- Metastatic Castration-Resistant Prostate Cancer Treatment Study
- Nanoknife Device Study in Prostate Cancer
- Novel Treatment Combination Study for Metastatic Prostate Cancer Patients
- Phase 1 Study for Urothelial Cancer
- Prostate Cancer Study
- SBRT for Localized Prostate Cancer Study
- Study of Atezolizumab with Bevacizumab in Advanced Bladder Cancer
- Study of Combination Therapy for High Risk Prostate Cancer
- Study of Standard Systemic Therapy in Treating Prostate Cancer
- Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer
- Systematic Light Exposure to Prevent Fatigue in Prostate Cancer Patients
- The ICONIC Trial for Rare Genitourinary Cancers
- The PROBE Trial: Treatment Study for Metastatic Kidney Cancer
- Treating Participants With Metastatic Prostate Cancer
- Treating Patients With High Risk Prostate Cancer
- Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
- Treatment Study for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
- Treatment Study for Node-Positive Prostate Cancer After Radical Prostatectomy
- Treatment Study for Patients with Advanced or Metastatic Solid Tumors
- Treatment Study for Patients With Localized Muscle Invasive Bladder Cancer
- Treatment Study for Patients With Locally Advanced Bladder Cancer
- Treatment Study for Patients With Muscle-Invasive Bladder Cancer
- Treatment Study for Patients with Prostate Cancer
- Treatment Study for Patients with Prostate Cancer with DNA Repair Defects
- Treatment Study for Patients with Selected Incurable Cancers
- Treatment Study for Rare Genitourinary Cancers
Gynecologic Cancers
- A Study of Serum Folate Levels in Patients Treated with Olaparib
- Study of a GITR Agonistic Antibody as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- The INNOVATE-3 Study for Patients with Recurrent Ovarian Cancer
- Treatment Stud for Advanced-Stage Cervical and Vaginal Cancers
- Treatment Study for Newly Diagnosed Advanced or Recurrent Endometrial Cancer
- Treatment Study for Patients with Cervical or Vaginal Cancer
- Treatment Study for Patients with Recurrent, Refractory, or Metastatic Endometrial Cancer
- Treatment Study for Patients with Stage I-IIA Cervical Cancer
- Treatment Study for Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Treatment Study for Recurrent Platinum-Resistant Ovarian Cancer
Head and Neck Cancer
- Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Experimental Drug Treatment Study for Patients with Specific Solid Tumors
- HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Treatment Study
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Lenvatinib in Combination with Pembrolizumab vs. Standard Chemotherapy in Head and Neck Cancer
- Locoregionally Advanced Head and Neck Cancer Treatment Study
- Nasal and Paranasal Sinus Cancer Treatment Study
- Nasal and Paranasal Sinus Squamous Cell Carcinoma Treatment Study
- Oropharyngeal Cancer Treatment Study
- Photoimmunotherapy Study in Recurrent Head and Neck Cancer
- Study of a GITR Agonistic Antibody as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Testing Immunotherapy Versus Observation in Patients with HPV Throat Cancer
- The ASPEN-03 Study for Patients with Head and Neck Cancer
- The ASPEN-04 Study for Patients with Head and Neck Cancer
- The PATHWay Study for Patients with Head and Neck Cancers
- Treatment Study for Patients with Head and Neck Squamous Cell Carcinoma
- Treatment Study for Patients with Human Papilloma Virus Associated Head and Neck Squamous Cancer
- Treatment Study for Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
- Treatment Study for Patients with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Cancer
- Treatment Study for Squamous Cell Carcinoma of the Head and Neck
Lung and Chest Tumors
- A Lung-MAP Non-Match Treatment Trial: Treating Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer
- A LUNG-MAP Treatment Trial: Combination Treatment for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation
- A LUNG-MAP Treatment Trial: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
- A Lung-MAP Treatment Trial: Treating Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer
- ALCHEMIST Chemo-IO Study: Treatment for Treatment for Non-Small Cell Lung Cancer
- An ALCHEMIST Treatment Trial: Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
- Chemoradiation With or Without Atezolizumab in Treating Patients with Limited Stage Small Cell Lung Cancer
- Drug Treatment Study for Small Cell Lung Cancer
- Early Stage Unresected Non-Small Cell Lung Cancer Treatment Study
- Experimental Drug Treatment Study for Patients with Specific Solid Tumors
- Limited Stage Small Cell Lung Cancer Treatment Study
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
- Maintenance Chemotherapy Study in Treating Patients With Stage IV Non-small Cell Lung Cancer
- Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Stage IV Non-Small Cell Lung Cancer Study
- Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer Study
- Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer
- Non-Small Cell Lung Cancer Treatment Study
- Radiation Therapy Treatment Study for Patients with Limited-Stage Small Cell Lung Cancer
- Stages II and III Non-Small Cell Lung Cancer Treatment Study
- Study for Patients with Completely Resected Stage IB to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- Study of a GITR Agonistic Antibody as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Study of Advanced Non-Small Cell Lung Cancer that has Progressed on First-Line Osimertinib Therapy
- Study of First Line Treatment and Maintenance in Non-Small Cell Lung Cancer
- Study of Immunotherapy Alone or with Chemotherapy as Treatment in Non-Small Cell Lung Cancer
- Surgically Resected ALK-Positive Early Stage Non-Small Cell Lung Cancer Treatment Study
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Testing the Addition of an Antibody to Standard Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- The (TKI)-naïve Study for Patients with NSCLC
- The ALCHEMIST Screening Trial: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer
- The Canakinumab Study for Patients with AJCC/UICC
- The Encorafenib and Binimetinib Study for NSCLC Patients
- The MAVERICK Trial for Small-Cell Lung Cancer
- The PF-06946860 Study for Patients With NSCLC and Cachexia
- The Venetoclax Study for NSCLC Patients with PD-L1
- The Venetoclax Study with Previously Untreated NSCLC Patients
- Treatment Study for Patients with Advanced or Metastatic Solid Tumors
- Treatment Study for Patients with Newly Diagnosed Stage III Non-Small Cell Lung Cancer
- Treatment Study for Patients with Selected Incurable Cancers
- Treatment Study of Pill Chemotherapy Compared to Standard Chemotherapy for Non-Small Cell Lung Cancer
Melanoma and Soft Tissue
- A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
- A Study to Compare Treatments Before and After Surgery for High-Risk Melanoma
- Advanced Squamous Skin Cancer Treatment Study
- Drug Treatment Study with Radiation in Advanced Tumors
- Pivot-12 Study for Melanoma
- STAMP Study: Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
- Treating Patients With Advanced Skin Squamous Cell Cancer
- Treatment Study For Patients With Advanced BRAFV600 Mutant Melanoma
- Treatment Study for Patients With Desmoplastic Melanoma
- Treatment Study for Patients with Selected Incurable Cancers
- Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma
- UV1-202 Vaccine Study in Combination with Nivolumab and Ipilimumab for Melanoma